| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/30/2004 | CN1155402C Compounds that inhibit interaction between signal-transducing proteins and GLGF(PDZ/DHR) domain and uses thereof |
| 06/30/2004 | CN1155399C Application of pilose gerbera herb in preparing antineoplastic medicine |
| 06/30/2004 | CN1155396C Medicine for guiding cancer cell differentiation and its use on treating and preventing cancer |
| 06/30/2004 | CN1155390C Application of N-gluco-N-bithiocarboxylic acid-L-amino acid sodium in repelling Pt |
| 06/30/2004 | CN1155387C Phosphonate medicine for treating osteoporosis and bone cancer transfer |
| 06/30/2004 | CN1155378C Antitumour synergistic composition |
| 06/30/2004 | CN1155376C 9-cis-retinonic acid and medicinal use of salt and ester thereof |
| 06/30/2004 | CN1155374C Novel biological activity of proglumide |
| 06/29/2004 | US6756491 Receptor polypeptide for use in the treatment of urogenital disorders and cushing's syndrome |
| 06/29/2004 | US6756481 IL-23 receptor binding compositions |
| 06/29/2004 | US6756480 Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
| 06/29/2004 | US6756397 Such as (s)-n-(2-((1-chloromethyl)-1,2-dihydro-5-((4-methylpiperazino)carbonyloxy) -3h-benz(e) indol-3-yl)carbonyl)-1h-indol-5-yl)-5-((3-methyldithio-1-oxopropyl)-amino) -1h-indole-2-carboxamide; enhanced water solubility and stability |
| 06/29/2004 | US6756391 Antiviral compounds |
| 06/29/2004 | US6756385 Imidazole derivatives |
| 06/29/2004 | US6756383 Such as 3-(2-(methoxycarbonyl)acetylamino)pyridine-4-carboxylic acid for treatment of diseases characterized by activity of vascular endothelial growth factor receptor tyrosine kinases; enzyme inhibitors |
| 06/29/2004 | US6756382 Amide substituted imidazoquinolines |
| 06/29/2004 | US6756381 A purified antitumor agent is crystallized from acetone or dichloromethane |
| 06/29/2004 | US6756375 Estrogen receptor modulation; hormone replacement therapy |
| 06/29/2004 | US6756374 Diaminothiazoles having antiproliferative activity |
| 06/29/2004 | US6756362 Anionic polymers including dermatan sulfate, chondroitin sulfate, keratan sulfate, heparan sulfate, heparin, dextran sulfate, pentosan polysulfate, hyaluronic acid and alginate. |
| 06/29/2004 | US6756201 Diagnostic methods and gene therapy using reagents derived from the human metastasis suppressor gene KAI1 |
| 06/29/2004 | US6756055 Administering to a mammal formulation of cationic lipids and a substance that affects angiogenesis; allowing formulation to associate with angiogenic endothelial cells of an angiogenic blood vesselsuch that it enters cells |
| 06/29/2004 | US6756047 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/29/2004 | US6756036 Methods for treating cancer using PSCA antibodies and fragments thereof |
| 06/29/2004 | CA2263913C Substituted 6,6-hetero-bicyclic derivatives |
| 06/29/2004 | CA2207404C Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase |
| 06/29/2004 | CA2112399C Methods and compositions for treating malaria and other diseases |
| 06/29/2004 | CA2031518C Endothelial cell-leukocyte adhesion molecules (elams) and molecules involved in leukocyte adhesion (milas) |
| 06/27/2004 | CA2451588A1 Protein having active sulfate transporter activity and method for detecting canceration of tissue |
| 06/27/2004 | CA2447352A1 Cancer preventive agent and food |
| 06/24/2004 | WO2004053487A1 METHOD OF DIAGNOSIS,TREATMENT AND USEFUL AGENTS FOR CONDITIONS CHARACTERISED BY MODULATION IN THE LEVEL OF ACTIVIN βC |
| 06/24/2004 | WO2004053138A1 Dec-205 (ly 75) / dcl-1 intergenic splice variants associated with hodkin’s disease, and uses thereof |
| 06/24/2004 | WO2004052921A1 Cyanomethyl derivatives as cysteine protease inhibitors |
| 06/24/2004 | WO2004052895A1 Colchicine derivatives, preparation method and use thereof |
| 06/24/2004 | WO2004052884A1 Anthranilic acid amide derivatives and their pharmaceutical use |
| 06/24/2004 | WO2004052880A1 Pyridine derivatives as jnk inhibitors and their use |
| 06/24/2004 | WO2004052873A2 Analogs of green tea polyphenols as chemotherapeutic and chemopreventive agents |
| 06/24/2004 | WO2004052866A1 3-phenyl-cinnoline homologue and antitumor agent containing the same |
| 06/24/2004 | WO2004052863A1 Anti-inflammatory agent |
| 06/24/2004 | WO2004052862A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof |
| 06/24/2004 | WO2004052847A2 Tricyclic steroid hormone nuclear receptor modulators |
| 06/24/2004 | WO2004052838A1 Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents |
| 06/24/2004 | WO2004052407A1 Ultrasound contrast using halogenated xanthenes |
| 06/24/2004 | WO2004052406A1 Coupling of dicarboxylic compounds by convertion into anhdrids |
| 06/24/2004 | WO2004052383A1 An composition containing triterpenoid saponins extracted from bamboo, and the preparation method and use thereof |
| 06/24/2004 | WO2004052369A1 Pharmaceutical combinations and methods for the treatment of leukemia |
| 06/24/2004 | WO2004052349A2 Compositions comprising a combination of diphenyl ura impdh inhibitors and apoptosis-inducing anti-cancer agents |
| 06/24/2004 | WO2004052315A2 Tyrosine kinase inhibitors |
| 06/24/2004 | WO2004052286A2 Tyrosine kinase inhibitors |
| 06/24/2004 | WO2004052282A2 Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| 06/24/2004 | WO2004052280A2 Anti-angiogenic compounds and their use in cancer treatment |
| 06/24/2004 | WO2004052276A2 Compositions and methods for the therapy and diagnosis of prostate cancer |
| 06/24/2004 | WO2004043982A3 Novel ampiphilic derivatives of alpha-c-phenyl n-tert-butyl nitrone |
| 06/24/2004 | WO2004041862A3 Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| 06/24/2004 | WO2004037286A3 Combination of a trioxopyrimidine compound inhibitor and an anti-tumor agent, and uses thereof |
| 06/24/2004 | WO2004035629A3 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 06/24/2004 | WO2004031236A3 Therapeutic uspa1-derived peptides |
| 06/24/2004 | WO2004026894A3 Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity |
| 06/24/2004 | WO2004024883A3 PAKs AS MODIFIERS OF THE CHK PATHWAY AND METHODS OF USE |
| 06/24/2004 | WO2004022716A3 Recombinatant mutants of rhabdovirus and methods of use thereof |
| 06/24/2004 | WO2004018044A8 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent |
| 06/24/2004 | WO2004014304A3 Electrospun amorphous pharmaceutical compositions |
| 06/24/2004 | WO2004008101A3 The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| 06/24/2004 | WO2003103583A3 A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
| 06/24/2004 | WO2003099221A3 Methods for using jnk inhibitors for treating or preventing disease-related wasting |
| 06/24/2004 | WO2003083083A3 Methods of using flt3-ligand in immunization protocols |
| 06/24/2004 | WO2003076631A3 Genetic products differentially expressed in tumors and use thereof |
| 06/24/2004 | WO2003051841A3 Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
| 06/24/2004 | WO2003018044A8 New drug |
| 06/24/2004 | WO2003015613A3 Molecular characteristics of non-small cell lung cancer |
| 06/24/2004 | WO2002092594A8 Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 06/24/2004 | WO2002072021A3 Agents and methods for the prevention of initial onset and recurrence of existing cancers |
| 06/24/2004 | WO2002036072A3 Method for short-term and long-term drug dosimetry |
| 06/24/2004 | US20040122279 Sterile radioactive seeds |
| 06/24/2004 | US20040122237 Substituted benzazoles and methods of their use as inhibitors of Raf kinase |
| 06/24/2004 | US20040122086 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 06/24/2004 | US20040122084 7-Methyl-3.6,10,15-tetraoxapentacyclo [12.2.1.02,4. 05,7. 09,13]heptadec-1(17)-ene-11,16-dione derivatives; antitumor, -proliferative, -carcinogenic agents; viricides;DNA polymerase inhibitors; bactericides; solubility; stability; injections |
| 06/24/2004 | US20040122083 Antitubulin assembly and cell growth inhibitor denominated "dioxostatin" |
| 06/24/2004 | US20040122079 (R)-thiophene-2,5-dicarboxylic acid 2-hydroxyamide 5-[(1-thiophen-2-yl-ethyl)-amide], e.g.: antiproliferative agents; anticarcinogenic agents; enzyme inhibitors of histonedeacetylases; colon, breast, lung, prostate, rectal, stomach, bladder cancers |
| 06/24/2004 | US20040122066 Oxadiazole derivatives having anticancer effects |
| 06/24/2004 | US20040122055 C10 carbonate taxane compositions |
| 06/24/2004 | US20040122052 Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with a 2,6-dioxo-3-hydroxypiperidin-5-yl group or derivative; selectively inhibit TNF alpha, useful in treating inflammation and effecting relaxation of airway smooth muscle |
| 06/24/2004 | US20040122047 Substituted tetrahydroisoquinolines |
| 06/24/2004 | US20040122041 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| 06/24/2004 | US20040122036 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 06/24/2004 | US20040122035 selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase-5 (PDE5); sexual disorders, cardiovascular disorders; 1-(2H-benzo[d]1,3-dioxolan-5-yl)(1,2,3,4-tetrahydro- beta -carbolin-2-yl)-2-naphthyl ketone for example |
| 06/24/2004 | US20040122030 Substituted phthalimide and isoquinoline derivatives; thalidomide analogs that lack the piperidine-2,6-dione moiety of thalidomide |
| 06/24/2004 | US20040122029 6-(4-Methoxy-phenyl)-8-phenyl-2-phenylamino-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one for example; anticancer agents; chemical intermediates |
| 06/24/2004 | US20040122027 Use of pyridoindolone derivatives for preparing anticancer medicines |
| 06/24/2004 | US20040122024 Effective against mutations; such as 2,3-Dihydro-4-ethyl-1-(3-methylphenylamino)-5-phenyl-1H-imidazole-2-thione |
| 06/24/2004 | US20040122020 Novel amides, preparation and therapeutic use as modulators of ccr-receptor activity |
| 06/24/2004 | US20040122018 Benzo(5,6)cyclohepta(1,2-b)pyridine derivatives; use in combination with antineoplastic agents such as cisplatin |
| 06/24/2004 | US20040122011 such as 3-[3-[N-isopropyl-N-(4-methoxyphenyl-sulfonyl)amino]-phenyl]-3-(3-pyridyl)-2(E)-propenohydroxamic acid; for treatment/prevention of neoplasia/inflammation; kits |
| 06/24/2004 | US20040122009 formed via cyanuric chloride; for treatment of cancer and proliferative diseases |
| 06/24/2004 | US20040122006 such as 7-[(2-aminophenyl)sulfanyl]-2H-1,4-benzoxazin-3(4H)-one; oxidation/reduction; deblocking/deprotectiing; cardiovascular disorders |
| 06/24/2004 | US20040122004 such as (1R,2R)-N-[(1S)-2-amino-1-(4-fluorophenyl)-2-oxoethyl]-2-(4-{[{[ethyl(2-hydroxyethyl)amino]carbonyl}(4-fluorophenyl)amino]methyl}phenyl)cyclohexanecarboxamide; for prevention/treatment of cardiovascular disorders |
| 06/24/2004 | US20040121981 Administering therapeutically effective amount of a compound which binds to a galectin |
| 06/24/2004 | US20040121979 Pharmaceutically active uridine esters |
| 06/24/2004 | US20040121976 Anti-inflammatory vectors |
| 06/24/2004 | US20040121972 Methylenetetrahydrofolate reductase inhibitors and uses thereof |